HNGE · Hinge Health, Inc. · Stock research

Current Thesis

The binary the June raise created resolved on 2026-08-04, and the two sessions that mattered came afterwards. Q2 2026 revenue printed $212.8M, +53% against $139.1M a year earlier, clearing the company's own $200–202M floor and a $201.03M Street estimate; adjusted EPS was $0.59. FY2026 guidance moved to $856–860M from $818–824M, Q3 was guided to $223–225M against a $211.00M consensus, and $105M of cash was committed to Cylinder Health, opening a third condition category behind musculoskeletal and migraine. Six firms raised targets on 2026-08-05: RBC to $110 from $75, Citizens to $107, Evercore ISI to $105, Wells Fargo to $103, Barclays to $100, Needham to $97 from $76.

The narrative leg on offer is the second half of a re-rate — a digital-MSK vendor being repriced as a multi-condition enterprise platform with software economics: 86% GAAP gross margin, a 29% non-GAAP operating margin, $100M of quarterly free cash flow and a GAAP crossover to $0.52 diluted EPS. The unresolved part is entirely in the tape. Back inside the band that produced the 2026-07-13 all-time intraday high of $91.50 and its $90.00 close. The next company-controlled event is roughly three months out.

Bullish and bearish views on Hinge Health, Inc.

The model's bull view on Hinge Health, Inc. (HNGE), in brief: Q2 2026 revenue $212.8M, +53% YoY, above the self-raised $200–202M range set at the 2026-06-09 Investor Day and above the $201.03M consensus (reported 2026-08-04). The bear view: A ten-dollar intraday give-back on the heaviest volume of the week happened at the same price band the July high sits in. Both cases follow in full.

Bull Case

• Q2 2026 revenue $212.8M, +53% YoY, above the self-raised $200–202M range set at the 2026-06-09 Investor Day and above the $201.03M consensus (reported 2026-08-04).
• Guidance raised at both ends on 2026-08-04: FY2026 to $856–860M from $818–824M with non-GAAP income from operations of $236–244M at a 28% margin, and Q3 to $223–225M versus $211.00M consensus.
• Cash conversion stepped up — free cash flow $100M in Q2 versus $33M in Q2 2025 (47% margin against 23%), with $476M of cash and equivalents before the Cylinder payment.
• Demand indicators tracked revenue: LTM calculated billings $862M, +52% YoY, and nearly 3,000 clients including more than half the Fortune 100 (2026-08-04 disclosure).
• New-condition attach is dated and countable: the migraine programme launched in Q1 2026 had 450+ clients and more than 5M lives by the 08-04 call, with management sizing 10–20bps of 2027 yield uplift.
• Cylinder Health adds ~100 clients across 2M lives and ties to two of the three largest PBMs for $105M cash, contributing $7–8M of 2026 revenue ahead of a 2027 GI launch.
• The peer read on the employer channel came back clean: Omada Health reported 2026-08-06 revenue of $88M, +43%, a second consecutive quarter of GAAP net income at $5M, members +45%, and raised FY2026 revenue guidance to $334–340M.
• The company kept buying its own stock while insiders sold — $196.5M repurchased since the November 2025 programme, and a 2026-07-29 board increase leaving $300.0M of authorization.

Bear Case

• A ten-dollar intraday give-back on the heaviest volume of the week happened at the same price band the July high sits in.
• Fifteen target raises between 2026-06-23 and 2026-08-05 now cluster at $97–$110. The published upside has moved to where the price already is, which removes the estimate-revision fuel that carried June and July.
• Insider distribution is scheduled and has been sold into strength: Insight-affiliated funds sold 426,000 shares at $90.21 on 07-07 and 07-09 for $38.4M — within days of the 07-13 high — after $61.8M of sales at $70.21–$71.67 on 06-22 through 06-24.
• Insight-affiliated funds retain Class B shares convertible into Class A, a supply pool sitting above the 45.39M reported float.
• No company-controlled catalyst exists between now and the Q3 print. The $105M Cylinder close is management-guided to end-August/early-September and is the only dated company item inside 30 days.
• Guided share count of 85–87M diluted sits above the 77.38M shares outstanding, so the per-share arithmetic behind the FY guide embeds further dilution.

Setup & Price Structure

Life-cycle: MATURING as of 2026-08-07. The narrative is well known and still working — it is no longer being discovered. What dates the label: the discovery phase was the 2026-06-09 mid-quarter raise into open price discovery above the $62.18 prior all-time high; the crowd caught up between 06-23 and 08-05 across fifteen target hikes, a Zacks newsletter mention on 07-21 and national coverage of the insider sales on 07-12. Fundamentals still surprised on 08-04, which is why this is not yet late-cycle, but the sell-side upside band and the price have converged.

The week's structure: 08-03 close $77.65 (+3.94%); 08-04 close $79.42 (+2.28%), high $81.67; 08-06 close $80.08 (−0.88%) on 1,755,093; 08-07 close $89.33 (+11.55%), range $80.36–$90.40 on 2,546,003. No dated company announcement accompanied the 08-07 move in the covered news flow, so the driver is unattributed.

That leaves a defined structure. Overhead: the $89.78–$91.50 band, tested 07-13, 08-05 and 08-07, with the 07-13 close of $90.00 unexceeded. Support: the 08-05 post-print low of $75.19 and the 08-03 pre-print close of $77.65, with a rising 50-day average last reported at $73.64 and a 200-day at $52.04 on 08-04 against a 52-week range of $30.08–$91.50.

Crowding observables, stated as observables: a 2026-08-07 close of $89.33 against that $73.64 fifty-day; 13.73% of a 45.39M float short at the latest update; six same-day target raises on 08-05 into a $97–$110 cluster; two Rule 10b5-1 programmes producing Form 4s on a calendar rather than on news; BlackRock's Schedule 13G filed 2026-07-28 for 2,992,772 Class A shares, 5.5% of the class; and $300.0M of remaining buyback authorization as a standing bid disclosed 2026-07-29.

Catalyst Calendar (next 30 days)

• 2026-08-14 — Q2 2026 13F filing deadline. Shows who owned the June–July advance as of June 30, and whether BlackRock's 5.5% Class A stake is matched by long-horizon holders or by fast money.
• ~2026-08-31 (est.) — expected close of the $105M Cylinder Health acquisition, guided to end-August/early-September on the 08-04 call. The raised FY2026 guide embeds $7–8M of Cylinder revenue.
• ~2026-11-03 (est.) — Q3 2026 results, the first test of the $223–225M Q3 guide and the $856–860M FY frame, and the first quarter where GI and migraine contribution become checkable.

Elapsed catalysts

• Ongoing — Rule 10b5-1 Form 4s from the executive chairman's plan adopted 2025-12-01 and Insight-affiliated fund plans; these have arrived monthly since June and are the mechanism by which supply reaches the $89–91.50 band. (passed 251d ago)

What Would Change Our Mind

The structure that has to hold is the post-print range built between 08-05 and 08-07. Losing it would mean the 53% growth quarter, the $35M-plus midpoint guidance raise and six target hikes bought nothing durable — a weekly close below $75 forfeits that range beneath the 08-05 low of $75.19 and puts the rising 50-day back in play. A second condition is the Cylinder close slipping past September, since $7–8M of the raised FY number depends on it. A third is the theme rolling to SATURATED: a further rejection at $91.50 with no new estimate revisions, or a first downgrade out of the $97–$110 cluster, would mark the sell-side as spent.

What would strengthen the case instead: a weekly close above $91.50 on volume above the 1,537,250-share twenty-day average, Cylinder closing on schedule, and Form 4 flow slowing rather than accelerating into the highs.

Correlation Notes

• The 2026-07-30 decoupling from Teladoc held. Teladoc's Q2 print showed revenue down 4%, a $38.9M net loss and cut full-year guidance, and its shares fell more than 28%; HNGE went on to print its highest close since 07-13 eight sessions later (Modern Healthcare Q2 health-tech recap).
• Omada Health is the closest listed read on employer digital-health budgets. Its 2026-08-06 report raised FY2026 revenue guidance to $334–340M and adjusted EBITDA to $21–27M, with shares +5.83% after hours to $20.68, and announced a CEO transition effective 2027-01-01 (Sean Duffy to Founder and Executive Chair, Wei-Li Shao to CEO). HNGE closed −0.88% that session and +11.55% the next, a sequence consistent with a channel-confirmation bid but not proof of one.
• The largest MSK competitor, Sword Health, is private, so pricing pressure in enterprise renewals shows up only indirectly — in calculated billings growth against the $862M LTM figure growing 52% as of 2026-08-04, rather than in a quoted peer.
• With 13.73% of a 45.39M float short and a twenty-day average near 1.54M shares, session moves in both directions carry a mechanical component that is separable from fundamental news only by looking at what was dated that day.